Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bob T Li

Showing results (61-70 of 139) with videos related to

Pageof 14
Sort By:
Histopathology|September 7, 2016
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare targetChristina I Selinger, Bob T Li, Nick Pavlakis, et al.
Advances in Radiation Oncology|April 11, 2025
Cell-Free Circulating Tumor DNA for NonInvasive Molecular Profiling Among Patients Undergoing Definitive Chemoradiation for Locally Advanced Lung CancerEmily S Lebow, Jordan Eichholz, Lillian Boe, et al.
JCO Precision Oncology|April 9, 2019
Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i>-Mutant Lung CancersMichael Offin, Romel Somwar, Natasha Rekhtman, et al.
Science Translational Medicine|October 5, 2022
A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting c-fosYuan Liu, Neel Chudgar, Brooke Mastrogiacomo, et al.
Nature Communications|August 17, 2023
Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasisAnna Skakodub, Henry Walch, Kathryn R Tringale, et al.
JAMA Network Open|November 12, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical TrialsPasi A Jänne, David Planchard, Koichi Goto, et al.
The Lancet. Oncology|March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trialEgbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.
The New England Journal of Medicine|September 17, 2021
Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung CancerBob T Li, Egbert F Smit, Yasushi Goto, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2023
Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with AlectinibEmily Miao, Jordan E Eichholz, Emily S Lebow, et al.
JCO Precision Oncology|March 9, 2022
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid TumorsPashtoon M Kasi, Gordon Fehringer, Hiroya Taniguchi, et al.
Pageof 14

Showing results (61-70 of 139) with videos related to

Sort By:
Pageof 14
Histopathology|September 7, 2016
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare targetChristina I Selinger, Bob T Li, Nick Pavlakis, et al.
Advances in Radiation Oncology|April 11, 2025
Cell-Free Circulating Tumor DNA for NonInvasive Molecular Profiling Among Patients Undergoing Definitive Chemoradiation for Locally Advanced Lung CancerEmily S Lebow, Jordan Eichholz, Lillian Boe, et al.
JCO Precision Oncology|April 9, 2019
Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i>-Mutant Lung CancersMichael Offin, Romel Somwar, Natasha Rekhtman, et al.
Science Translational Medicine|October 5, 2022
A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting c-fosYuan Liu, Neel Chudgar, Brooke Mastrogiacomo, et al.
Nature Communications|August 17, 2023
Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasisAnna Skakodub, Henry Walch, Kathryn R Tringale, et al.
JAMA Network Open|November 12, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical TrialsPasi A Jänne, David Planchard, Koichi Goto, et al.
The Lancet. Oncology|March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trialEgbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.
The New England Journal of Medicine|September 17, 2021
Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung CancerBob T Li, Egbert F Smit, Yasushi Goto, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2023
Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with AlectinibEmily Miao, Jordan E Eichholz, Emily S Lebow, et al.
JCO Precision Oncology|March 9, 2022
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid TumorsPashtoon M Kasi, Gordon Fehringer, Hiroya Taniguchi, et al.
Pageof 14